Overview

The nation is facing competing public health issues: the need to treat a large number of Americans with acute and chronic pain vs the crisis of opioid abuse. Pri-Med’s P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-25 curriculum focuses on improving practitioners’ ability to recognize, diagnose, and classify pain; educating clinicians on the full spectrum of pain management options, including non-opioid pharmacologic interventions; and providing risk reduction strategies through integration of opioids into individualized pain management plans. Clinicians will learn to recognize signs and symptoms of opioid dependence and abuse in order to optimally manage patients’ pain and medication use.

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.

Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies.
This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).

The content of this 1.5-hour course titled "P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025: Part 3" encompasses the required course for all DEA-authorized prescribers in Florida, including allopathic physicians, osteopathic physicians, dentists, podiatrists, and optometrists. In addition, this course satisfies the required controlled substance prescribing training for physician assistants and ARNPs in Florida.

Learning Objectives

  • Recognize best practices to reduce the risks associated with prescription of opioid analgesics, including safe storage and disposal
  • Anticipate and manage adverse effects of opioid use including signs of opioid overdose and the use of naloxone
  • Select approaches to safely initiate opioids for the treatment of acute pain and chronic pain
  • Identify strategies for ongoing safe and effective use of opioids in patients with chronic pain, including titration, referral, and discontinuation, when appropriate

EDUCATIONAL PARTNERS

Miller Medical Communications, LLC

Equity Commons

SUPPORTED BY

Opioid Analgesic REMS Program Companies